D ual antiplatelet therapy is a cornerstone for the management of patients with acute coronary syndrome (ACS). 1 Recently, new and more powerful alternative antiplatelet agents have been introduced into clinical practice. 2, 3 Among them, in the Platelet Inhibition and Patient Outcomes (PLATO) trial, ticagrelor was found to be significantly more effective than clopidogrel in preventing cardiovascular events in patients with ACS (number needed to treat =53). However, in the same study, treatment with ticagrelor was associated with a higher incidence of nonprocedural-related bleedings (number needed to harm =143).
The administration of a loading dose was scheduled in all patients randomized to ticagrelor in the PLATO trial, independent of any ongoing antiplatelet regimen, even those receiving ongoing clopidogrel therapy. Currently, no direct evidence is available on the need for a reload dose when switching from an ongoing clopidogrel to a ticagrelor antiplatelet regimen. A ticagrelor loading dose could be unnecessary for maintaining a constant level of platelet inhibition in patients already receiving clopidogrel therapy. Thus, in the present study, we sought to assess whether the administration of a ticagrelor loading dose provides further inhibition of platelet aggregation during the switch from ongoing clopidogrel-aspirin to ticagreloraspirin double antiplatelet therapy in patients with ACS.
Treatment to Ticagrelor in Patients With Acute Coronary Syndrome (SHIFT-OVER) study is a randomized, single-blinded, single-center trial. Consecutive patients diagnosed with ACS, and who were receiving clopidogrel treatment, were screened. All suitable patients who accepted to participate provided written informed consent and were randomly assigned to either a ticagrelor 90 mg (no loading dose, group 1) plus 90 mg bis in die (maintenance) or a 180 mg (loading dose, group 2) plus 90 mg bis in die (maintenance) in addition to aspirin treatment. None of the enrolled patients were actively receiving oral anticoagulation therapy; all patients were treated with a loading dose of aspirin (500 mg) at the moment of the acute event and were then administered aspirin (100 mg) once a day as a maintenance dose. The evening dose of ticagrelor was administered to all patients randomized in the SHIFT-OVER study starting on the day the therapeutic shift was performed. A high maintenance dose of clopidogrel (150 mg/die) was not allowed in the present study. The time from the initiation of clopidogrel to the therapeutic shift to ticagrelor, as well as the time interval from the index event to the shift to ticagrelor, was registered and reported (mean±SD).
All patients starting ticagrelor treatment during the study protocol continued to receive dual antiplatelet treatment with aspirin and ticagrelor beyond the end of the study and up to months after the acute event, according to the current treatment guidelines for ACS. 4, 5 Random allocation of patients was performed on the basis of a concealed randomization table that was previously generated using Research Randomizer (http://www.randomizer.org/form.htm). The study protocol was approved by the local institutional Ethics Committee. The trial protocol is registered within ClinicalTrials.gov.
Platelet aggregation was measured using point-of-care multiple electrode aggregometry (MEA; Dynabyte Medical, Munich, Germany) at multiple time-points (just before the first administration of ticagrelor and at 2, 6, 24, and 72 hours after the therapeutic switch to ticagrelor). Platelet aggregation was additionally measured at baseline and at 2 and 24 hours after the therapeutic switch using traditional light transmission aggregometry (LTA; AggRAM Analyzer System; Helena Laboratories Inc, Beaumont, TX) to verify the reproducibility of the results. The 24-and 72-hour measurements were performed in the morning, just before the administration of the morning ticagrelor dose. Hence, the time between the last ticagrelor maintenance dose and the platelet function test was 12 hours for these measurements. The following exclusion criteria were applied: age <18 and >80 years, percutaneous coronary intervention in the previous 6 months, ongoing ticagrelor, prasugrel or ticlopidine therapy, contraindication to ticagrelor therapy, reloading with clopidogrel after the initial loading dose, administration of glycoprotein IIb/IIIa inhibitors until 6 days before the treatment randomization, resistance to clopidogrel, concomitant neoplastic or immune-mediated pathologies, liver cirrhosis, severe pulmonary pathologies, hemorrhagic diathesis, previous stroke, actual pregnancy, ongoing pharmacological treatment with p450 cytochrome inhibitors until 15 days before the randomization, thrombocytopenia, or anemia (hemoglobin, <10 g/ dL). The inclusion/exclusion criteria used in the SHIFT-OVER study are listed in the Table I in the Data Supplement. The primary end point of the SHIFT-OVER study was the difference in residual platelet aggregation levels, as determined by MEA, 2 hours after the therapeutic shift from clopidogrel to ticagrelor between the 2 study arms (loading dose and no loading dose groups). Secondary study end points included platelet aggregation results across all timepoints and the occurrence of clinical events within 30 days.
Blood Sampling
Blood samples were obtained through venous puncture. All blood samples were analyzed after a resting phase of 30 minutes. Hemoglobin levels, hematocrit values, platelet counts, and white blood cell counts were measured in 2.7-mL tubes containing 1.6 mg EDTA/mL blood. For MEA, blood samples were collected in 3-mL hirudin tubes (Verum Diagnostica GmbH, Munich, Germany), whereas LTA blood samples were collected in 0.35-mL sodium citrate (3.8%) Vacutainer Blood Collection Tubes (Becton; Dickinson and Company, Franklin Lakes, NJ).
Assays for Platelet Function

Point-of-Care Whole Blood MEA
Whole blood platelet aggregometry was performed using a Multiplate platelet analyzer, which provides 2 independent measuring units, each consisting of 2 conductive wires. During analysis, the sample-reagent mixture is automatically stirred using a discardable PTFE-coated magnetic stirrer (800 U/min). The instrument continuously measures the change in resistance, which is proportional to the amount of platelets adhering to the electrodes and transforms it to arbitrary aggregation units (AU); these values are plotted against time (min), and the area under the aggregation curve (AUC=AU×min) is calculated from the mean values of the 2 curves. To simplify the numbers, AU×min were finally converted to units (U), where 10 AU×min correspond to 1 U (U). ΔU indicates the difference between aggregation levels measured at T0 (before the first administration of ticagrelor) and T2 (2 hours after the first ticagrelor administration). The result was considered acceptable when the difference between the 2 curves is <20%. Briefly, 300 μL of saline were added to whole blood at 37°C. After a 3-minute incubation, 20 μL of the selected agonist solution was added to obtain a final concentration of 0.5 mmol/L arachidonic acid (ASPITEST; Dynabyte, Munich, Germany), 6.4 μmol/L ADP (ADP-Test; Dynabyte), or 32 μmol/L thrombin receptor-activating peptide (TRAP-Test; Dynabyte).
Light Transmission Aggregometry
Platelet aggregation was also measured by LTA using the AggRAM Analyzer System. To avoid trauma, blood samples were collected in 0.35-mL sodium citrate (3.8%) Vacutainer Blood Collection Tubes. Platelets were prepared according to a standard procedure. 6 Briefly, samples were centrifuged for 15 minutes at 1000 RPM to obtain platelet-rich plasma. Platelet-poor plasma was obtained via further centrifugation for 10 minutes at 3500 RPM, and it was used as blank reference. Platelet aggregation was evaluated using 450 μL of platelet-rich plasma after stimulation with 20 mmol/L ADP (Helena BioSciences Europe, Tyne and Wear, United Kingdom). All measurements were obtained within 2 hours of sample collection, and the results are reported as maximal aggregation. Δ represents the mean difference between the aggregation levels measured at T0 (before the first administration of ticagrelor) and T2 (2 hours after the first ticagrelor administration).
WHAT IS KNOWN
• Ticagrelor had higher efficacy on clinical end points when compared with clopidogrel in patients with acute coronary syndrome in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
• In the PLATO trial, the switch from ongoing clopidogrel therapy to ticagrelor was performed with the administration of a ticagrelor loading dose.
• It is unknown whether the administration of a ticagrelor loading dose is essential during the therapeutic switch from ongoing dual antiplatelet therapy, including clopidogrel to ticagrelor.
WHAT THE STuDy ADDS
• Avoidance of the ticagrelor loading dose at the switch from ongoing clopidogrel does not significantly influence the level of platelet aggregation in patients with acute coronary syndrome.
• These results may be of practical interest for the management of high bleeding-risk patients, such as older patients or those with chronic kidney disease, encountered in the daily clinical routine. February 2014
Bleeding Assessment and Classification
Bleeding events were classified according the Bleeding Academic Research Consortium classification. Briefly, bleedings were considered minor if classified as type 1 to type 2, and they were considered major if classified as type 3 to type 5. 7
Statistical Methods
Continuous variables are presented as the mean±SD unless otherwise noted. Categorical variables were compared using the χ 2 test. One-way ANOVA testing was used to compare approximately normal distributed variables. Lin concordance correlation was used to compare results from MEA and LTA. The Mann-Whitney U test was used to compare between 2 groups with non-normally distributed variables. The Wilcoxon rank test was used to compare paired groups. On the basis of previously published platelet aggregation results, we determined that a sample size of 24 subjects for each group was needed to achieve 80% power and to detect a 20% difference in aggregation levels between the experimental groups, with a type I error of 5%. [8] [9] [10] To account for patients who, despite being randomly assigned to 1 group, could change the treatment group for any reason, we added 1 additional subject to each group, resulting in a final sample size of 25 subjects per experimental group.
Because platelet aggregation was repeatedly measured within the same subjects, a repeated measure fixed effects model was used to account for time-correlation and modified treatments over time in the primary analysis. In this model, MEA aggregation levels were used as the within-subject factor, and 5 time-points were considered (0, 2, 6, 24, and 72 hours). The treatment group (loading dose versus no loading dose) was selected as the between-subjects factor. All additional variables were treated as covariates. The Mauchly test was used to measure the assumption of sphericity, whereas multivariate tests were conducted using the Pillai trace test and further validated with the following additional tests: Wilks lambda, Hotelling trace, and Roy largest root. The same statistical analyses were applied to the LTA results. Statistical significance was assumed at P<0.05. All statistical analyses were performed using SPSS software (version 20.0; Chicago, IL).
Results
Patient Population
A total of 50 patients were consecutively randomized in a 1:1 fashion to either group 1 (switch to ticagrelor [90 mg BID] without loading dose) or group 2 (switch to ticagrelor [180 mg] with loading dose). No statistically significant differences were observed in demographic variables, baseline routine laboratory variables, or medications between the 2 study arms ( Tables 1 and 2 ).
In addition, mean platelet count at baseline was similar between the 2 study arms (220±73×10 3 /μL in group 1 versus 233±84×10 3 /μL in group 2; P=0.576).
The mean time from the index event to enrollment was of 115±151 hours, and the time interval for which patients were on clopidogrel therapy before switching to ticagrelor was 110±147 hours.
The mean time from the last maintenance dose of clopidogrel to the first platelet function test (the baseline T0 evaluation) was 22±4.9 hours. The time from the last ticagrelor maintenance dose and the 24-and 72-hour platelet function tests was 12 hours because the tests were performed just before the administration of the morning ticagrelor dose, as described in the protocol.
Of the 50 randomized patients, 48 underwent coronary revascularization (45 percutaneous coronary intervention and 3 coronary artery bypass grafting) and 2 patients did not receive any revascularization.
In this study, 21 patients presented a ST-segment-elevation myocardial infarction, 23 presented a non-ST-segmentelevation myocardial infarction, and 6 presented an unstable angina ( Table 1 ).
Platelet Aggregation Analysis
Platelet aggregation was evaluated using 2 different techniques: whole blood MEA and traditional LTA. We observed a significant concordance between the ADP-induced aggregometry obtained with the MEA (ADP-MEA) and Results of platelet aggregation test for both MEA and LTA are displayed in Figure 1 and Table 3 . No relevant difference in platelet aggregation was observed between the 2 study arms at baseline, as determined by MEA (34.4±12.9 U in group 1 versus 41.7±20 U in group 2; P=0.256) or LTA (24±17% in group 1 versus 25±14% in group 2; P=0.535).
Residual platelet aggregation was significantly reduced in both arms 2 hours after the first administration of ticagrelor (ΔU 16.8±11; P<0.001 in group 1 and ΔU 23.6±19.9; P<0.001 in group 2), as determined using MEA. Similar results were obtained with LTA (Δ 15±15%; P<0.001 in group 1 and Δ 16±14%; P<0.001 in group 2). Interestingly, no difference was observed in residual platelet aggregation after the therapeutic switch to ticagrelor between group 1 (no ticagrelor loading dose) and group 2 (ticagrelor loading dose). Indeed, residual platelet aggregation 2 hours after the switch to ticagrelor was 17.6±7.2 U in group 1 versus 18.1±6 U in group 2 (P=0.281) using MEA and 9±4% in group 1 versus 9±3% in group 2 (P=0.698) using LTA. Similar levels of residual platelet aggregation were observed throughout the time course of the study. In particular, residual platelet aggregation at 6 hours was 15±5.3 U in group 1 versus 14.6±6 U in group 2 (P=0.756) using MEA. Similarly, residual aggregation levels at 24 hours were 17.4±10.5 U in group 1 versus 18.8±5.6 U in group 2 (P=0.165) using MEA and 9±4% in group 1 versus 9±3% in group 2 (P=0.600) using LTA. The same trend was maintained at 72 hours after the shift to ticagrelor because residual platelet aggregation was 19.1±8.1 U in group 1 versus 22.9±6.1 U in group 2 using MEA (P=0.117).
Because platelet aggregation was repeatedly measured in the same subjects, statistical analysis was performed using a repeated-measures ANOVA. This analysis confirmed that the study treatment (loading dose versus no loading dose) had no effect on platelet aggregation. In addition, neither the time interval from initiation of clopidogrel administration to the shift to ticagrelor nor pretreatment aggregation level had any statistically significant effect (P>0.05 for all variables; Table 4 ). Notably, the assumption of sphericity was met at the Mauchly test of sphericity, and the results were consistent across 4 different test used (Pillai trace, Wilks lambda, Hotelling trace, and Roy largest root).
In addition, the same analysis was repeated after the addition of the following covariates: time interval from the acute event to shift to ticagrelor, presence of hypertension, and presence of diabetes mellitus. These additional analyses provided similar results, confirming that these covariates did not influence the study outcome ( Table 5) .
The same repeated-measures analysis was performed for LTA results, confirming that the study treatment (loading dose versus no loading dose) did not influence platelet aggregation, as measured using LTA. In addition, neither the Table 6 ). Because the assumption of sphericity was not met using the Mauchly test of sphericity, the statistics were recalculated after adjusting the degrees of freedom of the F test by means of the following 3 methods: the lower-bound test, the Greenhouse-Geisser test, and the Huynh-Feldt test. These corrections provided similar results, confirming that there was no influence on the study outcome (P>0.05 for all analyses). Furthermore, there was no evidence of nonlinear effects.
ADP-induced PLT-aggregation
In line with previous reports, baseline platelet aggregation was slightly higher in patients with diabetes mellitus when compared with those with non-diabetes mellitus (41.4±16.5 U versus 36.5±17.3 U) although this difference was not statistically significant (P=0.253). Accordingly, the time course of platelet aggregation in the subgroup with diabetes mellitus displayed a similar trend to that of the general study population (Table 7 ; Figure 2 ), confirming that ticagrelor maintains its efficiency in inhibiting platelet aggregation in patients with diabetes mellitus. Repeated-measures ANOVA confirmed that the study treatment (loading dose versus no loading dose) did not influence platelet aggregation. Moreover, neither the time interval from initiation of clopidogrel administration to the shift to ticagrelor nor pretreatment aggregation levels had a statistically significant effect (P>0.05 for all variables; Table 8 ). Similar results were found using LTA. However, because the assumption of sphericity was not met in the latter case using the Mauchly test of sphericity, the statistics were recalculated after adjusting the degrees of freedom of the F test, as described above (Table 9) .
No statistically significant differences were observed after comparing the platelet aggregation results between the 2 treatment groups (ticagrelor loading versus no loading) within the 3 subgroups (ST-segment-elevation myocardial infarction, non-ST-segment-elevation myocardial infarction, or unstable angina; Table 10 ), with the exception of the 72-hour platelet function test by MEA. However, this difference was not confirmed by repeated-measures analysis (P>0.05).
Next, we performed a multivariate analysis to test for predictors of ticagrelor response at 72 hours, including age, sex, body mass index, diabetes mellitus, hypertension, smoking, creatinine, and administration of a ticagrelor loading dose. Interestingly, hypertension was the only independent predictor of the response to ticagrelor (P=0.002).
Accordingly, receiver operating curve analysis revealed that residual platelet aggregation was unable to identify patients who had received a loading dose of ticagrelor ( Figure 3 ) at either 2 hours after the first administration (AUC, 0.589; P=0.282 for MEA and AUC, 0.468; P=0.698 for LTA) or after 24 hours (AUC, 0.614; P=0.165 for MEA and AUC, 0.543; P=0.600 for LTA). No significant difference in residual platelet aggregation was observed between men and women at baseline (P=0.685), as well as 2 hours (P=0.122) and 24 hours after the switch (P=0.375), as measured using MEA. Similar results were confirmed using LTA.
Differences in Platelet Aggregation Depend on P2y12 Inhibition
To confirm that the observed results were related to P2Y12 inhibition and not to other platelet anomalies, we measured TRAP-2-induced platelet aggregation. There was no difference in TRAP-2-induced platelet aggregation between the 2 study arms throughout the course of the study. In fact, residual TRAP-2-induced platelet aggregation was 95.2±23.8 U in group 1 versus 92.7±20.1 U in group 2 at baseline (P=0.900), 89.3±27 U in group 1 versus 75.1±26.8 U in group 2 at 2 hours (P=0.091), 88.8±79.2 U in group 1 versus 79.1±31.4 U in group 2 at 6 hours (P=0.204), 82.8±26.8 U in group 1 versus 84.2±22.3 U in group 2 at 24 hours (P=0.555), and 95.3±25.1 U in group 1 versus 94.4±20.2 U in group 2 at 72 hours (P=0.987). Arachidonic acid-induced platelet aggregation was measured as an internal control (Table 11 ). 
Clinical Events at 30-Day Follow-up
Clinical follow-up at 30 days after the switch from clopidogrel to ticagrelor was available for 48 of the 50 enrolled patients. No deaths nor strokes were reported during the follow-up period. A total of 2 patients underwent a new hospitalization within 30 days of the shift to ticagrelor. Among these, 1 patient was referred to the hospital by the general practitioner because of the onset of atrial fibrillation; he was successfully cardioverted to sinus rhythm and discharged the day after. One patient was hospitalized for a planned cardiovascular rehabilitation program.
One additional patient was readmitted beyond the 30-day observational period for a planned coronary revascularization (coronary artery bypass grafting), which was successfully performed without procedural complications. Importantly, no major bleedings were observed in either group. Few minor bleedings were reported within 30 days (n=9), but there was no statistically significant difference between the groups (P=0.064). The observed minor bleedings included epistaxis in 2 patients, gingival bleeding in 2 patients, minor subcutaneous ecchymosis in 3 patients, slight hematuria in 1 patient, and small blood loss from preexisting hemorrhoids in 1 patient. Spontaneous resolution was observed in all the reported cases, and no interruption or modification of dual antiplatelet therapy was necessary. Table 12 displays a complete list of all 30-day clinical events.
Discussion
The major finding of this randomized, single-blinded study was that the therapeutic switch from ongoing clopidogrel to ticagrelor treatment without the administration of a loading dose of ticagrelor seems to be safe and yields a similar level of residual platelet aggregation when compared with patients who received a ticagrelor loading dose.
Our results are based on the point-of-care MEA test, and traditional LTA was performed at baseline and after 2 and 24 hours as a methodological control. All results were obtained in a population of patients with ACS, the only clinical setting in which ticagrelor treatment is currently approved. 4, 5 Our results have important clinical implications for the management of antiplatelet therapy in patients with ACS. Indeed, at present, a loading dose of ticagrelor is administered in most centers because all patients enrolled in the large PLATO trial received a loading dose of the new drug, regardless of the previous antiplatelet regimen. 2 However, there is no direct evidence supporting the need to reload patients when switching from an ongoing clopidogrel to the ticagrelor antiplatelet regimen. This study is the first to address whether a loading dose should be administered when switching from ongoing clopidogrel to ticagrelor treatment. In particular, avoiding the administration of the loading dose of ticagrelor could limit bleeding events, especially during the critical periprocedural phase, in which the patient is already treated with several anticoagulants and antiplatelet agents. In fact, indepth analysis of the results from PLATO revealed that a higher number of bleeding events were reported within 30 days in the ticagrelor-treatment group (2.45%; 229 bleeding events) when compared with that in the comparator group (2.0%; 186 bleeding events) although this difference was not statistically significant. In fact, even after adjusting for several baseline variables, Figure 2 . Aggregation curves measured by multielectrode (MEA) and light transmission aggregometry (LTA) in patients with diabetes mellitus. Baseline platelet (PLT) aggregation was slightly higher in patients with diabetes mellitus when compared with those with non-diabetes mellitus, and a time course of platelet aggregation in the subgroup with diabetes mellitus displayed a similar trend as was observed in the general study population. a clear trend toward a higher rate of non-coronary artery bypass grafting-related major bleeding in ticagrelor-treatment arm was evident within the first 30 days of treatment (hazard ratio, 1.23; 95% confidence interval, 0.98-1.54; P=0.073). The lack of a statistically significant difference can be explained by the overall low bleeding event rate registered in PLATO. In fact, despite the large number of patients enrolled in the PLATO trial, this comparison was grossly underpowered (power, ≈60%). In addition, in the same study, ticagrelor was associated with a significant increase in non-coronary artery bypass grafting-related major or minor bleeding during the first 30 days (5.11 versus 4.02%; hazard ratio, 1.28; 95% confidence interval, 1.10-1.501; P=0.002); the latter comparison being significant with a higher statistical power (power, ≈95%). 2, 11 Interestingly, in the present study, residual platelet aggregation 2 hours after the first ticagrelor administration was comparable between the 2 groups, and these values were maintained throughout the time course, up to 72 hours after the switch. Moreover, a consensual reduction in TRAP-2induced aggregation was observed at 2 hours, confirming the high efficacy of the antiplatelet action of ticagrelor.
The therapeutic switch from ongoing clopidogrel treatment to a newer, more efficient antiplatelet agent was recently addressed for prasugrel in 2 independent studies. 12, 13 In the SWitching Anti Platelet (SWAP) study, although a similar level of platelet inhibition was observed in the 2 study arms after 7 days of maintenance treatment, more pronounced inhibition was achieved at 2 hours and up to 7 days in patients who received a 60-mg prasugrel loading dose at therapeutic switch. 12 Similarly, Lhermusier et al 13 observed significantly higher inhibition of platelet aggregation in patients who received a loading dose. Moreover, they found that a half-dose (30 mg) of prasugrel reload was sufficient to obtain a similar level of platelet inhibition as the full loading dose (60 mg). In addition, in A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST-Elevation Myocardial Infarction (ACCOAST) trial, which compared a split loading dose of prasugrel (30 mg immediately after non-ST-segmentelevation myocardial infarction diagnosis and 30 mg at the time of percutaneous coronary intervention) versus a single 60-mg bolus administration at percutaneous coronary intervention, pretreatment with prasugrel did not reduce the rate of major ischemic events ≤30 days, but it increased the rate of major bleeding complications. 14 Our findings demonstrate that the administration of a loading dose of ticagrelor has virtually no additive effect on platelet aggregation or the onset of drug action in patients with ACS who were responders to dual antiplatelet therapy with aspirin and clopidogrel. In fact, the same reduction in platelet aggregation was achieved within 2 hours in both groups, independently of the administration of a ticagrelor loading dose. The latter point is important because a faster inhibition of platelet aggregation could be of pathophysiological relevance in the acute setting of coronary disease. Supporting this hypothesis, high on-treatment residual platelet reactivity is correlated with a substantial increase in the rate of clinical events, up to an absolute risk increase of 5.9%. 15 The excellent efficacy of ticagrelor is associated with a good safety profile. Evaluating the net clinical benefit of ticagrelor versus clopidogrel, taking into account the bleeding rate, yields a 3:1 likelihood of being helped versus harmed in the PLATO in favor of ticagrelor. 2 Nevertheless, the higher incidence of nonprocedure-related bleedings associated with ticagrelor when compared with the less effective thienopyridine clopidogrel (number needed to harm, 143) creates the need to reduce the concomitant bleeding risk. Of note, the rate of minor bleedings registered in the present study is higher than that was reported in the PLATO trial. However, this finding could be explained by several mechanisms. First, this study used a different bleeding classification. In fact, several events were classified as minor bleedings in the SHIFT-OVER study, even those that did not require medical intervention by a healthcare professional. In contrast, such events were listed as minimal bleedings in the PLATO trial. Moreover, the present study enrolled a higher risk patient group from a real-world population, which consequently had a higher bleeding risk, when compared with the PLATO trial. In fact, we registered a higher prevalence of diabetes mellitus in our study when compared with that in the PLATO trial (33% versus 25%), and our study encompassed a large majority of male patients (85% versus 72% in the PLATO).
PLT-aggregation 2h after
Notably, the baseline level of ADP-induced aggregation was low in this present study, which is not surprising given the high variability of platelet aggregation levels reported in different studies; this finding could be because of several reasons, such as different patient baseline characteristics, concomitant medications, and treatment adherence. An additional source of variation is the methodological set up for platelet aggregation analysis. This last point is not trivial because minimal protocol variations may have major influences on test results. Nevertheless, the baseline platelet aggregation observed in our study is comparable with several other studies in patients with ACS, with some authors reporting even lower mean ADPinduced platelet aggregation in response to clopidogrel treatment. 8 Furthermore, Storey et al 16 reported a 35±17% platelet inhibition with ongoing clopidogrel treatment. Such small differences can be explained by different patient baseline characteristics between the studies. Nonetheless, the baseline levels of platelet aggregation measured in this study did not affect the comparison between the 2 treatment arms. Interestingly, a significant and early reduction in platelet aggregation after administration of the first ticagrelor dose was evident, whereas aggregation levels at 2 hours correspond to those found in similar studies with P2Y12 antagonists, as determined by both at LTA and MEA. 9 Notably, after correcting platelet aggregation to baseline levels, no significant difference in platelet aggregation was observed between groups 1 and 2 at any time point (P=0.58 at 2 hours; P=0.61 at 6 hours; P=0.95 at 24 hours; P=0.24 at 72 hours). Accordingly, the addition of baseline aggregation levels as a covariate to the repeated-measures ANOVA model confirmed that baseline aggregation levels did not influence downstream platelet aggregation levels (P>0.05).
In conclusion, this study demonstrates for the first time that the administration of a loading dose of ticagrelor has no additive effect on platelet aggregation in patients with ACS receiving ongoing treatment with clopidogrel when switching to the more effective antiplatelet agent, ticagrelor. These findings generate the intriguing hypothesis that avoiding the loading dose of ticagrelor when switching the P2Y12 antiplatelet agent in clopidogrel-treated patients could be associated with a reduction in the incidence of bleeding complications, without affecting the efficacy profile of ticagrelor. If confirmed in future studies using clinical end points, this novel therapeutic schema would improve patient safety while maintaining the significant efficacy of ticagrelor for reduction of cardiovascular events. 
Limitations
This study was based on laboratory end points, and therefore, it was not powered to assess clinical efficacy, including clinically relevant bleeding events. However, although no serious adverse events were registered in our study (ie, no major bleeding events occurred within the 30-days follow-up), larger trials are required to confirm this finding, which should be adequately sized to evaluate appropriate clinical end points.
The LTA and MEA results in our study were not well correlated, even though a certain degree of concordance was present. This result is likely related to the higher methodological variability of LTA. In fact, LTA requires skilled personnel and lacks standardization among laboratories, making it difficult to use as a diagnostic method and causing inconsistent results. Not surprisingly, agreement between different platelet aggregation assays is low. 17 In contrast, MEA does not require time-consuming centrifugation steps, and it does not require large sample volumes and lengthy processing time, which also account for the high variability of LTA. 18 For these reasons, we selected MEA for our primary analysis because it strongly reduces many potential disadvantages of LTA; LTA was only performed at baseline, as well as 2 and 24 hours after the therapeutic switch as a methodological control.
Because the present study was based on an instrumental end point, namely the platelet aggregation test, we excluded clopidogrel-resistant patients. The main aim of this study was to verify that no adjunctive loading dose is necessary to maintain an adequate level of platelet inhibition. Of course, the exclusion of clopidogrel-resistant patients from the study represents a potential limitation for the clinical application of our findings because few centers systematically test their patients for resistance to clopidogrel.
